Advanced Therapy Medicinal Products (2023)

Providing healthcare professionals with a thorough understanding of Advanced Therapy Medicinal Products (ATMPs) is essential to ensure the effective transition of innovative treatments and care techniques from the bench to the bedside.

Discover therapeutic advances in standardized transplants, cell-based products, blood products, complex and personalized medicines and innovative drug combinations

Healthcare professionals and scientists interested in the emerging field of advanced therapies, including pharmacists, physicians, medical researchers, biologists, healthcare engineers, biostatisticians.

Prof. Chantal CSAJKA, Faculty of Science, University of Geneva and Prof. Lana KANDALAFT, Faculty of Biology and Medicine, University of Lausanne

Advanced therapy medicinal products (ATMPs) such as cell therapy, tissue-engineered medicine or immunotherapy, as well as innovative medicines like phage therapy or nanomedicine, are pushing the boundaries of currently available treatments. Oncology, reconstructive surgery, orthopaedic surgery, neurosurgery, blood transfusion, infectious diseases - clinical applications are numerous.

Providing healthcare professionals with a thorough understanding of these therapeutic breakthroughs is essential to ensure the effective transition of these innovative treatments and care techniques from the bench to the bedside.

Hold a bachelor’s or master’s degree from a Swiss or foreign university (HEU), from a University of Applied Sciences (HES), or hold another title deemed equivalent by the Steering Committee, and

Prof. Chantal CSAJKA, Full professor, Director of the Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL; School of Pharmaceutical Sciences, UNIGE

Prof. Lana KANDALAFT, Chief of Service - Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation - Ludwig Institute for Cancer Research

Prof. Patrycja NOWAK-SLIWINSKA, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE

Prof. Michel PRUDENT, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL

Dr Grégory RESCH, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL

Dr Grégory RESCH, Senior Lecturer, Head of the Bacteriophage and Phage Therapy Laboratory, Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL

Dr Jean-François BRUNET, Head of the Cell Manufacturing Center, Service of Pharmacy, Lausanne University Hospital and UNIL

Prof. Lana KANDALAFT, Chief of Service - Center of Experimental Therapeutics, Lausanne University Hospital and UNIL ; Associate Director for Clinical Translation - Ludwig Institute for Cancer Research

Prof. Alexandre HARARI, Associate Professor, Head of the Tumor Immunology laboratory, Department of Oncology, Lausanne University Hospital and UNIL

Dr Francesco CEPPI, Lecturer and Medical Oncologist, Unit of Pediatric Oncology Hematology, Lausanne University Hospital and UNIL

Prof. Patrycja NOWAK-SLIWINSKA, Associate Professor, Head of the Molecular Pharmacology Group, School of Pharmaceutical Sciences, UNIGE

Prof. Michel PRUDENT, Associate Professor, Head of Innovation and Therapeutic Products, Transfusion Interrégionale CRS SA; Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and UNIL

Prof. Gerrit BORCHARD, Full Professor, Head of the Biopharmaceutics laboratory, School of Pharmaceutical Sciences, UNIGE

Les termes utilisés pour désigner des personnes sont pris au sens générique; ils ont à la fois la valeur d’un masculin et d’un féminin.